What dose constraints do you use for 60 Gy in 15-20 fraction lung treatments that are adjacent to the hilum?
Answer from: Radiation Oncologist at Academic Institution
The LUSTRE trial, which is a Canadian RCT comparing SABR (60/8, 48/4) vs. 60/15 provides some max point constraints to address this for 15#. Swaminath, Clin Lung Cancer. 2017 Mar;18(2):250-254. Spinal Canal 36 GyEsophagus 48 GyBrachial Plexus 50 GyHeart 66 GyGreat Vessels 66 GyTrachea/PBT 66 GySkin ...
Comments
Radiation Oncologist at Radiation Medicine Associates Please remember that as an investigative protocol,...
Radiation Oncologist at McMaster University School of Medicine BR.25 dose constraints were more conservative than...
Radiation Oncologist at University of Toronto Agree with Anand - also note that for the BR.25 pr...
Answer from: Radiation Oncologist at Academic Institution
For tumors abutting the esophagus and PTV including a portion of the esophagus, what is your recommended dose fractionation? Esophageal Dmax is 50.5 Gy in SUNSET for 15 fraction regimen, which is difficult to achieve in this scenario without compromising PTV coverage. Thank you for your insight.&nbs...
Comments
Radiation Oncologist at McMaster University School of Medicine LUSTRE max point to the esophagus was even more co...
Radiation Oncologist at University of Washington Thank you!
Radiation Oncologist at University of Texas at Tyler The esophagus is not a fixed structure and undergo...
Answer from: Radiation Oncologist at Community Practice
Could someone post the PTV planning objectives on the LUSTRE protocol? Specifically with regards to heterogeneity within the PTV. Unfortunately, the trial protocol is paywalled and my institution doesn't subscribe to that journal.
Swaminath et al., PMID 27876603
Comments
Radiation Oncologist at Beaumont Health System @Jahan Mohiuddin
From your link, for the SBRT arm...
Radiation Oncologist at McMaster University School of Medicine To respond to the query, yes what is stated above ...
Please remember that as an investigative protocol,...
BR.25 dose constraints were more conservative than...
Agree with Anand - also note that for the BR.25 pr...